Last reviewed · How we verify
ACT-293987
ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.
ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis. Used for Pulmonary arterial hypertension (PAH), Chronic thromboembolic pulmonary hypertension (CTEPH).
At a glance
| Generic name | ACT-293987 |
|---|---|
| Sponsor | Actelion |
| Drug class | Soluble guanylate cyclase (sGC) stimulator |
| Target | Soluble guanylate cyclase (sGC) |
| Modality | Small molecule |
| Therapeutic area | Pulmonary Hypertension / Fibrosis |
| Phase | Phase 3 |
Mechanism of action
The drug directly activates soluble guanylate cyclase independently of nitric oxide, leading to increased production of cyclic GMP (cGMP), a key second messenger that promotes smooth muscle relaxation and vasodilation. This mechanism is particularly relevant in pulmonary hypertension and fibrotic diseases where impaired NO-sGC-cGMP signaling contributes to pathology.
Approved indications
- Pulmonary arterial hypertension (PAH)
- Chronic thromboembolic pulmonary hypertension (CTEPH)
Common side effects
- Headache
- Dizziness
- Hypotension
- Dyspepsia
Key clinical trials
- Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension (PHASE2)
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PHASE3)
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (PHASE3)
- Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension
- Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (PHASE3)
- Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-293987 CI brief — competitive landscape report
- ACT-293987 updates RSS · CI watch RSS
- Actelion portfolio CI